Arbutus Biopharma Corp
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
ABUS$3.82+2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Management Contract or Compensatory Arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on November 10, 2026.
| ARBUTUS BIOPHARMA CORPORATION | |
| By: | /s/ Lindsay Androski |
| Lindsay Androski | |
| President and Chief Executive Officer | |
| (Principal Executive Officer) | |
| By: | /s/ Tuan Nguyen |
| Tuan Nguyen | |
| Chief Financial Officer | |
| (Principal Financial Officer and Principal Accounting Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.